We further conducted subgroup analysis in DLBCL patients (N=38), and the results showed that TP53-mutated DLBCL patients had a significantly unfavorable prognosis compared to TP53 wild-type DLBCL patients (P=0.0047, Supplementary Figure 2A). The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.